Approximately 2.3 million Americans suffer from uveitis, and vision-loss resulting from uveitis accounts for 10-15% of blindness in the United States. æCurrent diagnostic methods require biopsy samples to be shipped to a laboratory for analysis. æThe gold standard technique is enzyme-linked immunosorbent assay (ELISA), which quantifies levels of disease biomarker (e.g. VEGF). æStandard ELISA techniques require multiple washing steps, trained technicians, and a dedicated facility. æThis method is expensive and time consuming. æWe have developed a microfluidic, centrifugal-based immunoassay as an attractive alternative to ELISA, capable of analysis at the point-of-care. ææThe device is composed of a compact disc equipped with microfluidic channels filled with density media, ELISA reagents, and assay beads. æWashing and separation steps become automated as centrifugal forces propel beads through the microfluidic channels. æAfter biopsy procurement, the sample is injected onto our ñlab-on-a-diskî device, and following a short incubation time (10 minutes) the device is analyzed on a dedicated reader. æThis platform eliminates the need for dedicated technicians, and preserves the integrity of the biopsy sample via immediate analysis. æThe implementation of our low-cost platform has the potential to reduce the number of people that suffer from complications due to uveitis via immediate detection and quantification of disease, as well as monitoring the efficacy of treatment.